✦ LIBER ✦

O-011 Azacitidine (AZA) + idarubicin (IDA) in untreated high-risk MDS – A GFM phase I/II study

✍ Scribed by Ades, L.; De Renzis, B.; Jeddi, R.; Delaunay, J.; Braun, T.; Hunault-Berger, M.; Stamatoullas, A.; Sanhes, L.; Samey, B.; Chermat, F.; Meddeb, B.; Fenaux, P.

Book ID: 122418237
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 69 KB
Volume: 37
Category: Article
ISSN: 0145-2126
DOI: 10.1016/S0145-2126(13)70033-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

O-017 A Phase I/II trial of erlotinib (E

O-017 A Phase I/II trial of erlotinib (ERLO) in higher-risk MDS after azacitidine (AZA) failure

✍ Thepot, S.; Boehrer, S.; Prebet, T.; Beyne-Rauzy, O.; Wattel, E.; Delaunay, J.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 88 KB

Clofarabine in combination with a standa

Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)

✍ Willemze, R.; Suciu, S.; Muus, P.; Halkes, C. J. M.; Meloni, G.; Meert, L.; Karr 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 197 KB